Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a ...
A Prescription Drug User Fee Act target date of June 16, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...
A bill working its way through the Georgia legislature would allow pharmacists to distribute medications meant to prevent ...
Persons initiating nPEP should be informed that preexposure prophylaxis (PrEP) can reduce their risk for acquiring HIV in the case of repeat or continuing exposure after the nPEP course. HealthDay ...
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...
No significant reduction seen in risk for symptomatic SARS-CoV-2 infection with postexposure prophylaxis for 5 or 10 days. (HealthDay News) — Postexposure prophylaxis with nirmatrelvir-ritonavir for 5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results